NR 283 Quiz 2
Name
Chamberlain University
NR-293: Pharmacology for Nursing Practice
Prof. Name
Date
Authors: Jaime Weisel and Nnamdi Omeludike
Course: Pharmacology for Nursing Practice
Instructor: Professor Gloria King-Hoff
Date: December 2018
This project focuses on Symproic, an oral opioid antagonist medication. Symproic is primarily prescribed to individuals suffering from Opioid Induced Constipation (OIC). As noted in the Journal for Managed Care and Formulary Management, “Opioid-induced constipation (OIC), new or worsening constipation occurring when initiating, changing, or increasing opioid use, represents the most common of these GI effects” (Hu & Bridgeman, 2018, p. 601). The target audience for our educational brochure includes adult patients diagnosed with chronic pain, which may stem from various conditions and who are receiving opioid analgesics for pain management. Research on Symproic’s safety and efficacy in children has not been conducted, thus our focus will remain on adult patients.
The brochure aims to creatively inform our audience about the complications associated with opioid use, as well as the adverse effects that can arise from these medications, highlighting the necessity of Symproic in their treatment regimen. In addition, it will detail how Symproic can alleviate some of the negative side effects associated with opioid use. Furthermore, we intend to educate patients about the therapeutic benefits of Symproic when prescribed appropriately. According to Markham (2017), “Symproic was associated with significantly greater improvements from baseline in the frequency of bowel movements per week compared with placebo (n = 620) at all assessed time points (weeks 12, 24, 36, and 52)” (p. 925).
| Feature | Details |
|---|---|
| Medication Name | Symproic (Naldemedine) |
| Indication | Opioid Induced Constipation (OIC) |
| Target Population | Adults with chronic pain prescribed opioid analgesics |
| Mechanism of Action | Opioid antagonist that reduces constipation caused by opioids |
| Benefits | Increases bowel movement frequency and alleviates constipation |
| Key Study Findings | Significant improvement in bowel movement frequency compared to placebo (Markham, 2017) |
Constipation too? Ready to make a move? (n.d.). Retrieved from https://www.symproic.com/
Hu, K., & Bridgeman, M. B. (2018). Naldemedine (Symproic) for the treatment of opioid-induced constipation. P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management, 43(10), 601–627.
Kaufman, M. B. (2017). Pharmaceutical approval update. P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management, 42(8), 502–504. Retrieved from https://chamberlainuniversity.idm.oclc.org/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124448428&site=eds-live&scope=site
Markham, A. (2017). Naldemedine: First global approval. Drugs, 77(8), 923–927. http://dx.doi.org.chamberlainuniversity.idm.oclc.org
New drug approvals. (2017). P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management, 42(5), 296–297. Retrieved from https://chamberlainuniversity.idm.oclc.org/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=122620653&site=eds-live&scope=site
Symproic (Naldemedine Tablets): Side effects, interactions, warnings, dosage & uses. (n.d.). Retrieved from https://www.rxlist.com/symproic-drug.htm
Have a question or need support? Connect with our team today. We’re ready to assist you with personalized guidance to help you achieve your academic goals. Reach out via email, phone, or our easy-to-use contact form.
612-217-0144
info@hireonlineclasshelp.com
Get expert assistance to excel in your courses with personalized support. Our creative approach ensures your academic success every step of the way.
Our Services
Recent Posts
